Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection

<p>REC-3964 has been well tolerated in healthy volunteers with no reported serious adverse events. Recursion to explore initiating a Phase 2 proof-of-concept study in patients with recurrent Clostridioides difficile infection in 2024. SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/recursion-announces-completion-of-phase-1-study-for-rec-3964-for-clostridioides-difficile-infection/">Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>